The tight control of eIF4E offers a mechanism to modulate translational rates in response to stress conditions, oncogenic stimulation, and changes of synaptic plasticity [20, 21]; variations in eIF4E levels have been implicated in neurodevelopmental and neuropsychiatric disorders, including ASD and FXS [22, 23], as well as in cancer; eIF4E has thus been defined as an oncogene [14, 15, 24]. The gene discussed is EIF4E; the disease is fragile X syndrome.